|Title||Stem cell mobilization and collection in patients with liver cirrhosis.|
|Publication Type||Journal Article|
|Year of Publication||2008|
|Authors||Lorenzini S, Isidori A, Catani L, Gramenzi A, Talarico S, Bonifazi F, Giudice V, Conte R, Baccarani M, Bernardi M, Forbes SJ, Lemoli RM, Andreone P|
|Journal||Aliment Pharmacol Ther|
|Date Published||2008 May|
|Keywords||Adult, Aged, Antigens, CD, Antigens, CD34, Dose-Response Relationship, Drug, Feasibility Studies, Female, Glycoproteins, Granulocyte Colony-Stimulating Factor, Hematopoietic Stem Cell Mobilization, Humans, Leukapheresis, Liver Cirrhosis, Male, Middle Aged, Peptides, Peripheral Blood Stem Cell Transplantation, Treatment Outcome|
BACKGROUND: Bone marrow-derived stem cells (BMSC) and granulocyte colony-stimulating factor (G-CSF) have been proved to contribute to tissue regeneration after liver injury.
AIMS: To test the safety of G-CSF and define the exact dose capable of mobilizing BMSC in the majority of patients with liver cirrhosis; and to assess the feasibility of leukapheresis to collect BMSC from peripheral blood.
METHODS: In this study, we treated 18 patients affected by liver cirrhosis with increasing doses of G-CSF to mobilize CD34(+) and CD133(+) BMSC into the peripheral blood.
RESULTS: The dose-finding phase demonstrated that 15 microg/kg/day of G-CSF is the optimal dose to mobilize both CD34(+) and CD133(+) stem cells. Circulating BMSC were collected by a single step leukapheresis in three patients and the mean number of CD34(+) and CD133(+) cells cryopreserved was 1.3 +/- 0.7 and 1.2 +/- 0.5 x 10(6)/kg, respectively. No severe adverse events were observed during the drug administration and stem cell collection. Noteworthy is, none of the patients showed a significant modification of liver function.
CONCLUSIONS: Our study demonstrates that G-CSF administration and BMSC collection from the peripheral blood is possible and safe in patients with liver cirrhosis. The optimal dose to mobilize BMSC in cirrhotics is 15 microg/kg/day. At this dose, G-CSF does not seem to modify the residual liver function in cirrhotic patients.
|Alternate Journal||Aliment. Pharmacol. Ther.|